AppLovin [US03831W1080]: Wedbush reaffirms Buy rating and sets the price target at $545 (41% upside potential) Wedbush is very optimistic about AppLovin ahead of the upcoming fourth-quarter figures. Since its launch in November 2024, the commerce product has proven to be an important growth driver. It enables the integration of e-commerce ads into...
The Best Stocks Based on the Nicolas Darvas Method
Among the 2000 most traded stocks in the USA, the stock has reached a new 5-year high and has increased by at least +60% since its mid-year low.
| Rank | Stock | Price | Vol. Ind. | Dist. Low | New High |
|---|---|---|---|---|---|
| WKN | Symbol | |||||
| 1 | Axsome Therapeutics | 132.79 $ | 170.31 % | 75.74 % | 0 Tage |
| A2AA7B | AXSM | |||||
| 2 | Matrix Service | 15.32 $ | 135.26 % | 67.58 % | 0 Tage |
| 880420 | MTRX | |||||
| 3 | Zillow Group | 83.93 $ | 87.44 % | 64.05 % | 0 Tage |
| A14NX6 | ZG | |||||
| 4 | Selectquote | 6.20 $ | 74.66 % | 252.35 % | 0 Tage |
| A2P41W | SLQT | |||||
| 5 | Zillow Group (C) | 86.75 $ | 73.66 % | 64.12 % | 0 Tage |
| A14XZY | Z | |||||
| 6 | Carvana | 270.85 $ | 61.95 % | 117.74 % | 0 Tage |
| A2DPW1 | CVNA | |||||
| 7 | Triumph Group | 25.30 $ | 380.91 % | 129.79 % | 1 Tage |
| 903498 | TGI | |||||
| 8 | SpringWorks Therapeutics | 52.68 $ | 209.50 % | 86.74 % | 1 Tage |
| SWTX | |||||
| 9 | Cloudflare | 173.25 $ | 166.62 % | 131.37 % | 1 Tage |
| A2PQMN | NET | |||||
| 10 | Turning Point Brands | 68.37 $ | 142.86 % | 79.53 % | 1 Tage |
| A2AKAM | TPB | |||||
Subscribe now to see the full ranking
Already a subscriber? Login
Sample Issue
$
0
one issue
Bestseller
Trial Subscription
$
33
1 month
Carvana [US1468691027]: JPMorgan maintains an Overweight rating and raises the price target from $300 to $350 (41% upside potential) JPMorgan believes that Carvana will experience another year of outperformance in 2025, as the company continues its trend of positive revisions and has potential for further increases in its stock level. Investor focus...
Business Driver : The US biopharmaceutical company Axsome Therapeutics (AXSM) specializes in drugs for the treatment of central nervous system (CNS) disorders. One of the main growth drivers is the FDA-approved antidepressant Auvelity (AXS-05), while it also has another medication, Sunosi (Solriamfetol), for the treatment of adults suffering from excessive...